Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria

• •Diagnosed with cancer, stage 1-4.
• •Completed taxane- or platinum-based chemotherapy, vinca alkaloids, or bortezomib at least three months (90 days) ago. Current use of anti-estrogen therapy, Herceptin, or PARP inhibitors is okay.
• •Clinical diagnosis of chemotherapy-induced peripheral neuropathy by clinician. This will be based on symptom history (paresthesias, dysesthesias, allodynia), loss of deep tendon reflexes, decreased vibratory sensation, or the presence of symmetrical stocking-glove numbness or paresthesias beginning after neurotoxic chemotherapy.
• •Self-reported average neuropathic pain score of at least 4 on a 10-point scale over the past 1 month.
• •Age ≥ 18 years
• •Concomitant use of analgesics is permitted if the dose has been stable for at least 2 weeks prior to study enrollment (no new analgesics have been added, discontinued, or changed in the 2 weeks prior to randomization).
• •Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.